Navigation Links
Investigational Drug May Help Avert Blood Clots
Date:3/13/2009

Researchers say it works even when common blood thinners also are taken

FRIDAY, March 13 (HealthDay News) -- A drug derived from the magnolia tree appears to be safe and tolerable in preventing blood clots, according to a phase 2 study conducted by researchers at the Duke Clinical Research Institute.

The trial included 1,030 people, 45 years and older, who were scheduled to undergo either percutaneous coronary intervention (PCI) -- a procedure to clear clogged arteries and keep them open with stents -- or angiography and then PCI. People having PCI are usually prescribed drugs, such as aspirin or clopidogrel, to prevent potentially dangerous blood clots.

The study participants were randomly assigned to receive one of three doses (10, 20 or 40 milligrams) of the new drug, called SCH 530348, or a placebo. Aspirin and clopidogrel were not prescribed as part of the study but were allowed, and 95 percent of people in the study took both drugs, the researchers said.

They found that the new drug was generally tolerable at all dosing levels and did not increase bleeding, even when taken with aspirin and clopidogrel. Bleeding occurred in 2 percent of the 129 people who took 10 mg, in 3 percent of those who took 20 mg, in 4 percent of those who took 40 mg and in 3 percent of the placebo group.

Participants were also given different maintenance doses of the drug. Bleeding occurred in 2 percent of those who took 0.5 mg, in 4 percent who took 1 mg, in 3 percent who took 2.5 mg and in 2 percent of those who took the placebo.

The findings were released online and published in the March 14 print issue of The Lancet. The study was funded by Schering-Plough, and a number of the study's authors received consulting fees from the drug maker or own stock in the company.

The researchers said that SCH 530348 appears able to uncouple two important functions of thrombin in the formation of blood clots and that it might offer a better way to control bleeding and blot clot formation during PCI. Thrombin is a protein in the blood that activates platelets, particles that clump together to form the scaffolding of a clot. Thrombin also helps produce fibrin, a protein that plays an important role in repairing damaged tissue.

"One of the intriguing things about this new investigational compound is that it blocks the thrombin receptor that activates platelet formation yet preserves the beneficial activity of fibrin formation." Dr. Richard Becker, a cardiologist and the study's lead author, said in a Duke news release. "And the data to date indicate the compound does this even when patients are taking aspirin and clopidogrel."

An international, phase 3 study of the new drug is under way, the researchers said.

More information

The American Heart Association has more about PCI.



-- Robert Preidt



SOURCE: Duke Medicine, news release, March 12, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
2. PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
3. Tibotec presents interim findings for TMC435, an investigational genotype 1 hepatitis C treatment
4. Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
5. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
6. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
7. Arthrosurface HemiCAP(R) Focal Knee Resurfacing Implant Receives FDA Approval to Move into Final Investigational Stage
8. NEW DATA FOR PAZOPANIB - GSKS LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS
9. Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms
10. UAB study shows investigational drug may treat biliary cancers
11. Investigational anti-restenosis drug pimecrolimus disappoints
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Investigational Drug May Help Avert Blood Clots
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: